Optimistic Buy Rating for Arcturus Therapeutics Amid Promising Cystic Fibrosis Treatment Developments

William Blair analyst Myles Minter has reiterated their bullish stance on ARCT stock, giving a Buy rating on March 27.

Myles Minter’s rating is based on the potential of Arcturus Therapeutics’ proprietary technologies, STARR and LUNAR, which have recently received regulatory approvals in Japan and the EU. Despite some challenges in the vaccine segment, the focus has shifted to the promising interim Phase II data for ARCT-032 in cystic fibrosis, expected in the second quarter of 2025.
Minter is optimistic about the results from the prior Phase Ib study, which showed a 4% increase in FEV1 in cystic fibrosis patients following ARCT-032 treatment. This increase was achieved alongside existing Trikafta treatment, and the upcoming Phase II study will evaluate patients not on background therapy. Arcturus has set a 3% FEV1 improvement threshold for advancing to further trials, aligning with industry standards. These factors contribute to Minter’s Buy rating for Arcturus Therapeutics.

According to TipRanks, Minter is a 3-star analyst with an average return of 3.6% and a 42.17% success rate. Minter covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Alnylam Pharma, and Arcturus Therapeutics.

In another report released on March 27, BTIG also maintained a Buy rating on the stock with a $58.00 price target.